CD274 and non-small cell lung carcinoma: In the current study, TTFields were shown for the first time to induce ICD in vivo and to be effective with concomitant anti-PD-1/anti-CTLA-4 or anti-PD-L1 therapy, supporting the emerging potential of TTFields therapy in the changing NSCLC immunotherapy landscape.